The historical rank and industry rank for Xlife Sciences AG's ROE % or its related term are showing as below:
XSWX:XLS'
s ROE % Range Over the Past 10 Years
Min: -7.28 Med: 6.41 Max: 31.29
Current: -7.22
During the past 8 years, Xlife Sciences AG's highest ROE % was 31.29%. The lowest was -7.28%. And the median was 6.41%.
XSWX:XLS's ROE % is ranked better than 71.89% of 1256
companies
in the Biotechnology industry
Industry Median: -38.26
vs XSWX:XLS: -7.22
Xlife Sciences AG (XSWX:XLS) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Xlife Sciences AG ROE % Related Terms
Xlife Sciences AG ROE % Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xlife Sciences AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's ROE % distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Xlife Sciences AG (XSWX:XLS) has a ROE % of -12.54% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Xlife Sciences AG and its competitors. According to the industry distribution chart, Xlife Sciences AG ranks #353 out of 1256 companies in the Biotechnology industry, placing it in the top 28.1%.
Is Xlife Sciences AG's ROE % too high?
Xlife Sciences AG's current ROE % is -12.54%. Based on the distribution chart, Xlife Sciences AG ranks #353 out of 1256 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #353 out of 1256 companies for ROE %. This puts Xlife Sciences AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current ROE % is -12.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.30, compared to a current price of CHF20.90 — trading 186.3% above its estimated fair value. The current ROE % is -12.54%. Xlife Sciences AG's overall GF Score™ is 50/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current ROE % is -12.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF20.90 is trading 186.3% above its estimated GF Value™ of CHF7.30.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
ROE %: -12.54%
GF Value™: CHF7.30 vs. price of CHF20.90 (186.3% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score
Get the complete analysis for XSWX:XLS
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
